The immunoregulatory roles of natural killer T cells in cyclophosphamide-induced tolerance

Transplantation

Volumn 84, Issue 12, 2007, Pages 1686-1695

  Iwai, Toshiro ^a   Tomita, Yukihiro ^a,b   Shimizu, Ichiro ^a   Kajiwara, Takashi ^a   Onzuka, Tatsushi ^a   Okano, Shinji ^b   Yasunami, Yohichi ^c   Yoshikai, Yasunobu ^a   Nomoto, Kikuo ^a   Tominaga, Ryuji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c FUKUOKA UNIVERSITY   (Japan)

Author keywords

Cyclophosphamide; NKT; Tolerance; Transplantation

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 4; LY49 INHIBITORY RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LY49; RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BAGG ALBINO MOUSE; CHIMERA; CYCLOPHOSPHAMIDE INDUCED TOLERANCE; CYTOKINE RELEASE; DBA 2 MOUSE; DONOR; GRAFT RECIPIENT; GRAFT REJECTION; IMMUNOREGULATION; KNOCKOUT MOUSE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; SKIN ALLOGRAFT; SKIN GRAFT; SPLEEN CELL; TRANSPLANTATION TOLERANCE; WILD TYPE;

ANIMALS; CYCLOPHOSPHAMIDE; FLOW CYTOMETRY; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE AGENTS; KILLER CELLS, NATURAL; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; MODELS, ANIMAL; SKIN TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 37549006843     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000295933.94854.d4     Document Type: Article

References (46)

1. Moody DB, Porcelli SA. Intracellular pathways of CD1 antigen presentation. Nat Rev Immunol 2003; 3: 11.
2. Vincent MS, Gumperz JE, Brenner MB. Understanding the function of CD1-restricted T cells. Nat Immunol 2003; 4: 517.
3. Jiang S, Lechler RI, He XS, Huang JF. Regulatory T cells and transplantation tolerance. Hum Immunol 2006; 67: 765.
4. Brigl M, Brenner MB. CD1: Antigen presentation and T cell function. Annu Rev Immunol 2004; 22: 817.
5. Mattner J, Debord KL, Ismail N, et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 2005; 434: 525.
6. Cui J, Shin T, Kawano T, et al. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 1997; 278: 1623.
7. Mieza MA, Itoh T, Cui JQ, et al. Selective reduction of V alpha 14+ NK T cells associated with disease development in autoimmune-prone mice. J Immunol 1996; 156: 4035.
8. Slifka MK, Pagarigan RR, Whitton JL. NK markers are expressed on a high percentage of virus-specific CD8+ and CD4+ T cells. J Immunol 2000; 164: 2009.
9. Naiki Y, Nishimura H, Kawano T, et al. Regulatory role of peritoneal NK1.1+ alpha beta T cells in IL-12 production during Salmonella infection. J Immunol 1999; 163: 2057.
10. Zeng D, Lewis D, Dejbakhsh-Jones S, et al. Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease. J Exp Med 1999; 189: 1073.
11. Seino KI, Fukao K, Muramoto K, et al. Requirement for natural killer T (NKT) cells in the induction of allograft tolerance. Proc Natl Acad Sci U S A 2001; 98: 2577.
12. Ikehara Y, Yasunami Y, Kodama S, et al. CD4(+) Valpha14 natural killer T cells are essential for acceptance of rat islet xenografts in mice. J Clin Invest 2000; 105: 1761.
13. Jiang X, Shimaoka T, Kojo S, et al. Cutting edge: Critical role of CXCL16/CXCR6 in NKT cell trafficking in allograft tolerance. J Immunol 2005; 175: 2051.
14. Shin T, Mayumi H, Himeno K, Sanui H, Nomoto K. Drug-induced tolerance to allografts in mice. I. Difference between tumor and skin grafts. Transplantation 1984; 37: 580.
15. Mayumi H, Shin T, Himeno K, Nomoto K. Drug-induced tolerance to allografts in mice II. Tolerance to tumor allografts of large doses associated with rejection of skin allografts and tumor allografts of small doses. Immunobiology 1985; 169: 147.
16. Mayumi H, Himeno K, Shin T, Nomoto K. Drug-induced tolerance to allografts in mice. IV. Mechanisms and kinetics of cyclophosphamide-induced tolerance. Transplantation 1985; 39: 209.
17. Mayumi H, Himeno K, Tanaka K, et al. Drug-induced tolerance to allografts in mice. IX. Establishment of complete chimerism by allogeneic spleen cell transplantation from donors made tolerant to H-2-identical recipients. Transplantation 1986; 42: 417.
18. Tomita Y, Mayumi H, Eto M, Nomoto K. Importance of suppressor T cells in cyclophosphamide-induced tolerance to the non-H-2-encoded alloantigens. Is mixed chimerism really required in maintaining a skin allograft tolerance? J Immunol 1990; 144: 463.
19. Eto M, Mayumi H, Tomita Y, et al. Intrathymic clonal deletion of V beta 6+ T cells in cyclophosphamide-induced tolerance to H-2-compatible, Mls-disparate antigens. J Exp Med 1990; 171: 97.
20. Tomita Y, Nishimura Y, Harada N, et al. Evidence for involvement of clonal anergy in MHC class I and class II disparate skin allograft tolerance after the termination of intrathymic clonal deletion. J Immunol 1990; 145: 4026.
21. Eto M, Mayumi H, Tomita Y, et al. Sequential mechanisms of cyclophosphamide-induced skin allograft tolerance including the intrathymic clonal deletion followed by late breakdown of the clonal deletion. J Immunol 1990; 145: 1303.
22. Zhang QW, Mayumi H, Umesue M, et al. Fractionated dosing of cyclophosphamide for establishing long-lasting skin allograft survival, stable mixed chimerism, and intrathymic clonal deletion in mice primed with allogeneic spleen cells. Transplantation 1997; 63: 1667.
23. Maeda T, Eto M, Nishimura Y, et al. Role of peripheral hemopoietic chimerism in achieving donor-specific tolerance in adult mice. J Immunol 1993; 150: 753.
24. Yoshikawa M, Tomita Y, Uchida T, et al. Lack of pluripotent stem cell engraftment in cyclophosphamide-induced tolerance. Transplant Proc 1999; 31: 898.
25. Yoshikawa M, Tomita Y, Uchida T, et al. Cyclophosphamide 200 mg/kg lacks ability to induce pluripotent stem cell engraftment in mice. Transplant Proc 1999; 31: 1939.
26. Tomita Y, Yoshikawa M, Zhang QW, et al. Induction of permanent mixed chimerism and skin allograft tolerance across fully MHC-mismatched barriers by the additional myelosuppressive treatments in mice primed with allogeneic spleen cells followed by cyclophosphamide. J Immunol 2000; 165: 34.
27. Mayumi H, Nomoto K, Good RA. A surgical technique for experimental free skin grafting in mice. Jpn J Surg 1988; 18: 548.
28. Tomita Y, Khan A, Sykes M. Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a nonmyeloablative regimen. J Immunol 1994; 153: 1087.
29. Matsuda JL, Naidenko OV, Gapin L, et al. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J Exp Med 2000; 192(5): 741.
30. Sonoda KH, Faunce DE, Taniguchi M, et al. NK T cell-derived IL-10 is essential for the differentiation of antigen-specific T regulatory cells in systemic tolerance. J Immunol 2001; 166: 42.
31. Shimizu I, Tomita Y, Zhang QW, et al. Different expressions of Ly-49 receptors on mouse NK and NK T cells. Immunobiology 2001; 204: 466.
32. Toyabe S, Seki S, Iiai T, et al. Requirement of IL-4 and liver NK1+ T cells for concanavalin A-induced hepatic injury in mice. J Immunol 1997; 159: 1537.
33. Miyamoto M, Emoto M, Brinkmann V, et al. Cutting edge: Contribution of NK cells to the homing of thymic CD4+NKT cells to the liver. J Immunol 2000; 165: 1729.
34. Iwai T, Tomita Y, Zhang QW, et al. Requirement of a higher degree of chimerism for skin allograft tolerance in cyclophosphamide-induced tolerance. Transpl Int 2005; 17: 795.
35. Arase H, Arase N, Ogasawara K, et al. An NK1.1+ CD4+8- single-positive thymocyte subpopulation that expresses a highly skewed T-cell antigen receptor V beta family. Proc Natl Acad Sci U S A 1992; 89: 6506.
36. Kawano T, Cui J, Koezuka Y, et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997; 278: 1626.
37. Yoshimoto T, Paul WE. CD4pos, NK11pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J Exp Med 1994; 179: 1285.
38. Cui J, Watanabe N, Kawano T, et al. Inhibition of T helper cell type 2 cell differentiation and immunoglobulin E response by ligand-activated Valpha14 natural killer T cells. J Exp Med 1999; 190: 783.
39. Burdin N, Brossay L, Kronenberg M. Immunization with alpha- galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis. Eur J Immunol 1999; 29: 2014.
40. Singh N, Hong S, Scherer DC, et al. Cutting edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J Immunol 1999; 163: 2373.
41. Oh K, Kim S, Park SH, et al. Direct regulatory role of NKT cells in allogeneic graft survival is dependent on the quantitative strength of antigenicity. J Immunol 2005; 174: 2030.
42. Vance RE, Jamieson AM, Raulet DH. Recognition of the class Ib molecule Qa-1(b) by putative activating receptors CD94/NKG2C and CD94/NKG2E on mouse natural killer cells. J Exp Med 1999; 190: 1801.
43. Smith HR, Chuang HH, Wang LL, et al. Nonstochastic coexpression of activation receptors on murine natural killer cells. J Exp Med 2000; 191: 1341.
44. Voyle RB, Beermann F, Lees RK, et al. Ligand-dependent inhibition of CD1d-restricted NKT cell development in mice transgenic for the activating receptor Ly49D. J Exp Med 2003; 197: 919.
45. Skold M, Cardell S. Differential regulation of Ly49 expression on CD4+ and CD4-CD8- (double negative) NK1.1+ T cells. Eur J Immunol 2000; 30: 2488.
46. Eto M, Hackstein H, Kaneko K, et al. Promotion of skin graft tolerance across MHC barriers by mobilization of dendritic cells in donor hemopoietic cell infusions. J Immunol 2002; 169: 2390.